Hidden myelodysplastic syndrome (MDS): A prospective study to confirm or exclude MDS in patients with anemia of uncertain etiology.


Journal

International journal of laboratory hematology
ISSN: 1751-553X
Titre abrégé: Int J Lab Hematol
Pays: England
ID NLM: 101300213

Informations de publication

Date de publication:
Feb 2019
Historique:
received: 07 06 2018
revised: 30 08 2018
accepted: 07 09 2018
pubmed: 6 10 2018
medline: 21 3 2019
entrez: 6 10 2018
Statut: ppublish

Résumé

Diagnosis of myelodysplastic syndromes (MDSs) when anemia is the only abnormality can be complicated. The aim of our study was to investigate the primary causes of anemia and/or macrocytosis of uncertain etiology. We conducted a multicenter, prospective study over 4 months in three hematology laboratories. In step 1, we used an automated informatics system to screen 137 453 hemograms for cases of anemia and/or macrocytosis (n = 2702). In step 2, we excluded all patients whose anemia appeared to be due to a known cause. This left 290 patients had anemia of uncertain etiology. In step 3, we conducted further investigations, including a peripheral blood smear, and analysis of iron, vitamin B12, folate, and thyroid hormone levels. A differential diagnosis was obtained in 139 patients (48%). The primary causes of anemia were iron deficiency (n = 59) and megaloblastic anemia (n = 39). In total, 25 hematologic disorders were diagnosed, including 14 patients with MDS (56%). The median age of MDS patients was 80 years, 12 had anemia as an isolated cytopenia, and most (n = 10) had lower-risk disease (IPSS-R ≤ 3.5). SF3B1 mutations were most frequent (n = 6) and correlated with the presence of ring sideroblasts (100%) and associated with better prognosis (P = 0.001). Our prospective, four-step approach is an efficient and logical strategy to facilitate the diagnosis of MDS on the basis of unexplained anemia and/or macrocytosis, and may allow the early diagnosis of the most serious causes of anemia. Molecular analysis of genes related to MDS could be a promising diagnostic and prognostic approach.

Identifiants

pubmed: 30290085
doi: 10.1111/ijlh.12933
doi:

Substances chimiques

Phosphoproteins 0
RNA Splicing Factors 0
SF3B1 protein, human 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

109-117

Informations de copyright

© 2018 John Wiley & Sons Ltd.

Auteurs

José María Bastida (JM)

Hematology, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain.

Oriana López-Godino (O)

Hematology, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain.

Ana Vicente-Sánchez (A)

Hematology, Hospital de la Ribera, Valencia, Spain.

Santiago Bonanad-Boix (S)

Hematology, Hospital de la Ribera, Valencia, Spain.

Blanca Xicoy-Cirici (B)

Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Badalona, Spain.

Jesus M Hernández-Sánchez (JM)

Instituto de Investigacion Biomedica de Salamanca, IBMCC, Centro de Investigacion del Cancer, Universidad de Salamanca-CSIC, Salamanca, Spain.

Esperanza Such (E)

Hematology, Laboratorio de Citogenética y Biología Molecular, Hospital Universitari i Politècnic La Fe, Valencia, Spain.

Jose Cervera (J)

Hematology, Laboratorio de Citogenética y Biología Molecular, Hospital Universitari i Politècnic La Fe, Valencia, Spain.

Juan C Caballero-Berrocal (JC)

Hematology, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain.

Félix López-Cadenas (F)

Hematology, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain.

Mario Arnao-Herráiz (M)

Hematology, Hospital de la Ribera, Valencia, Spain.

Inés Rodríguez (I)

Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Badalona, Spain.

Inmaculada Llopis-Calatayud (I)

Hematology, Hospital de la Ribera, Valencia, Spain.

María J Jiménez (MJ)

Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Badalona, Spain.

Maria Consuelo Del Cañizo-Roldán (MC)

Hematology, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain.

Maria Díez-Campelo (M)

Hematology, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH